Aaron Joseph Tande

Aaron Joseph Tande

Auto-generated profile, based on publicly available information

Aaron Joseph Tande

Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic , Rochester, Minnesota

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
DTDon Bambino Geno Tai
Don Bambino Geno Tai
RPRobin Patel
Robin Patel
MAMatthew P. Abdel
Matthew P. Abdel
EBElie F. Berbari
Elie F. Berbari
ATAaron J. Tande
Aaron J. Tande

12 July 2023 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SNSandra B. Nelson
Sandra B. Nelson
Jodian Amor PinkneyJodian Amor Pinkney
Jodian Amor Pinkney
ACAntonia F Chen
Antonia F Chen
ATAaron J Tande
Aaron J Tande
Over the last several decades, periprosthetic joint infection has been increasing in incidence and is occurring in more complex patients. While there have been advances in both surgical and medical treatment strategies, there remain important gaps in our understanding. Here, we share our current approaches to the diagnosis and management of periprosthetic joint infection, focusing on frequent clinical challenges and collaborative interdisciplinary care.

10 March 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ATAaron J Tande
Aaron J Tande
BPBenjamin D Pollock
Benjamin D Pollock
NSNilay D Shah
Nilay D Shah
GFGianrico Farrugia
Gianrico Farrugia
AVAbinash Virk
Abinash Virk
EBElie F Berbari
Elie F Berbari
Several vaccines are now available under emergency use authorization in the United States and have demonstrated efficacy against symptomatic COVID-19. Vaccine impact on asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is largely unknown. We conducted a retrospective cohort study of consecutive, asymptomatic adult patients (n = 39 156) within a large US healthcare system who underwent 48 333 preprocedural SARS-CoV-2 molecular screening tests between 17 December 2020 and 8 February 2021. The primary exposure of interest was vaccination with ≥1 dose of an mRNA COVID-19 vaccine. The primary outcome was relative risk (RR) of a positive SARS-CoV-2 molecular test among those asymptomatic persons who had received ≥1 dose of vaccine compared with persons who had not received vaccine during the same time period. RR was adjusted for age, sex, race/ethnicity, patient residence relative to the hospital (local vs nonlocal), healthcare system regions, and repeated screenings among patients using mixed-effects log-binomial regression. Positive molecular tests in asymptomatic individuals were reported in 42 (1.4%) of 3006 tests and 1436 (3.2%) of 45 327 tests performed on vaccinated and unvaccinated patients, respectively (RR, .44; 95% CI, .33–.60; P < .0001). Compared with unvaccinated patients, risk of asymptomatic SARS-CoV-2 infection was lower among those >10 days after the first dose (RR, .21; 95% CI, .12–.37; P < .0001) and >0 days after the second dose (RR, .20; 95% CI, .09–.44; P < .0001) in the adjusted analysis. COVID-19 vaccination with an mRNA-based vaccine showed a significant association with reduced risk of asymptomatic SARS-CoV-2 infection as measured during preprocedural molecular screening. Results of this study demonstrate the impact of the vaccines on reduction in asymptomatic infections supplementing the randomized trial results on symptomatic patients.

31 October 2014 in mBio
Verified
Journal Article
Open access
PDF file
ATAaron J Tande
Aaron J Tande
DODouglas R Osmon
Douglas R Osmon
KGKerryl E Greenwood-Quaintance
Kerryl E Greenwood-Quaintance
TMTad M Mabry
Tad M Mabry
AHArlen D Hanssen
Arlen D Hanssen
RPRobin Patel
Robin Patel
Small colony variants (SCVs) are naturally occurring subpopulations of bacteria. The clinical characteristics and treatment outcomes of patients with prosthetic joint infection (PJI) caused by staphylococcal SCVs are unknown. This study was a retrospective series of 113 patients with staphylococcal PJI, with prospective testing of archived sonicate fluid samples. SCVs were defined using two-investigator review. Treatment failure was defined as (i) subsequent revision surgery for any reason, (ii) PJI after the index surgery, (iii) prosthesis nonreimplantation due to ongoing infection, or (iv) amputation of the affected limb. There were 38 subjects (34%) with SCVs and 75 (66%) with only normal-phenotype (NP) bacteria. Subjects with SCVs were more likely to have been on chronic antimicrobials prior to surgery ( P = 0.048), have had prior surgery for PJI ( P = 0.03), have had a longer duration of symptoms ( P = 0.0003), and have had a longer time since joint implantation ( P = 0.007), compared to those with only NP bacteria. Over a median follow-up of 30.6 months, 9 subjects (24%) with SCVs and 23 (32%) with only NP bacteria experienced treatment failure ( P = 0.51). Subjects infected with Staphylococcus aureus were more likely to fail than were those infected with Staphylococcus epidermidis (hazard ratio [HR], 4.03; 95% confidence interval [CI], 1.80 to 9.04). While frequently identified in subjects with PJI and associated with several potential predisposing factors, SCVs were not associated with excess treatment failure compared to NP infections in this study, where they were primarily managed with two-stage arthroplasty exchange. IMPORTANCE Bacteria with the small colony variant (SCV) phenotype are described in small case series as causing persistent or relapsing infection, but there are insufficient data to suggest that they should be managed differently than infection with normal-phenotype bacteria. In an effort to investigate the clinical importance of this phenotype, we determined whether SCVs were present in biofilms dislodged from the surfaces of arthroplasties of patients with staphylococcal prosthetic joint infection and assessed the clinical outcomes associated with detection of SCVs. We found that prosthetic joint infection caused by SCV staphylococci was associated with a longer duration of symptoms and more prior treatment for infection but not with an increased rate of treatment failure, compared to infection caused by normal-phenotype staphylococci.

1 February 2016 in The American Journal of Medicine
Verified
Journal Article
Closed access
ATAaron J. Tande
Aaron J. Tande
BPBharath Raj Palraj
Bharath Raj Palraj
DODouglas R. Osmon
Douglas R. Osmon
EBElie F. Berbari
Elie F. Berbari
LBLarry M. Baddour
Larry M. Baddour
MSMuhammad Rizwan Sohail
Muhammad Rizwan Sohail

1 June 2017 in Infectious Disease Clinics of North America
Verified
Journal Article
Closed access
ATAaron J. Tande
Aaron J. Tande
EGEric O. Gomez-Urena
Eric O. Gomez-Urena
EBElie F. Berbari
Elie F. Berbari
DODouglas R. Osmon
Douglas R. Osmon